Phibro Animal Health Reports Strong Q3 Results, Raises Full-Year Guidance
PAHC has more than doubled off its 52-week low of $18.89.
Summary
Phibro Animal Health reported strong Q3 results with double-digit growth in net sales, net income, and EPS, leading the company to raise its full-year fiscal 2026 financial guidance.
Key Events · Earnings and Guidance · PAHC
-
Strong Q3 Financial Performance
For the quarter ended March 31, 2026, net sales increased 10% to $383.5 million, net income rose 15% to $24.0 million, and diluted EPS grew 16% to $0.59. Adjusted EBITDA also increased 11% to $60.8 million.
-
Raised Fiscal Year 2026 Guidance
The company updated its full-year fiscal 2026 guidance, increasing the lower end of several ranges. New guidance includes net sales of $1.46 billion to $1.50 billion, net income of $92 million to $100 million, and adjusted EBITDA of $247 million to $255 million.
-
Enhanced Financial Flexibility
After quarter end, the company increased its revolving credit facility by $125 million, from $310 million to $435 million, strengthening its liquidity and operational flexibility.
-
Strategic Initiatives Launched
Phibro announced the launch of its Sustainable Solutions Platform, including the introduction of VERRATAIN™ Verified Sustainability Solutions, indicating a focus on long-term strategic growth.
Analysis · PAHC · Life Sciences
Phibro Animal Health Corporation delivered robust third-quarter results, surpassing expectations with significant year-over-year growth across key financial metrics. The company's decision to raise its full-year fiscal 2026 guidance, increasing the lower end of several ranges, signals strong operational momentum and improved outlook. This positive financial update follows recent strategic moves, including an expanded revolving credit facility and the launch of a new Sustainable Solutions Platform, which collectively enhance the company's financial flexibility and long-term growth prospects. Investors should view this as a strong indicator of continued performance, despite a recent regulatory development in Brazil affecting certain products, which the company appears to be navigating effectively.
At the time of this filing, PAHC was trading at $55.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.89 to $60.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.